Clinical Trial

Efficacy and Safety of Shexiang Baoxin Pill(MUSKARDIA) in the Treatment of Acute Myocardial Infarction

Study acronym: MUST Ⅱ
Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the value of Shexiang Baoxin Pill (MUSKARDIA) in patients with acute myocardial infarction (AMI) through a prospective, multicenter, pragmatic randomized controlled real-world study. It seeks to validate its efficacy in reducing cardiovascular event risk during the peri-PCI period, as well as its effects on cardiac function, quality of life , and relevant biomarkers. Through this research, we expect to provide higher-quality evidence for the application of SBP in AMI patients undergoing PCI, thereby further optimizing comprehensive treatment strategies for AMI.
Trial Details
NCT Number NCT07153744
Lead Sponsor Shanghai Hutchison Pharmaceuticals Limited
Collaborators: Shanghai Zhongshan Hospital, Huashan Hospital, Shanghai 10th People's Hospital, Shanghai 6th People's Hospital, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai East Hospital, Longhua Hospital, Second Affiliated Hospital of Soochow University, Affiliated Hospital of Jiangsu University, The First Affiliated Hospital with Nanjing Medical University, The First People's Hospital of Lianyungang, Huai'an First People's Hospital, Sir Run Run Shaw Hospital, Second Affiliated Hospital, Zhejiang University, School of Medicine, First Affiliated Hospital of Ningbo University, Shandong Provincial Hospital, Qianfoshan Hospital, Weihai Municipal Hospital, Weifang People's Hospital, Rizhao People's Hospital, The Affiliated Hospital of Qingdao University, Jining First People's Hospital, Linyi People's Hospital, Xiangya Hospital of Central South University, Second Xiangya Hospital of Central South University, Yueyang Central Hospital, The First Affiliated Hospital of University of South China, The Central Hospital of Shaoyang, The First People's Hospital of Changde City, Wuxi People's Hospital, Jinhua Central Hospital, The Third Affiliated Hospital of Wenzhou Medical University, Shuguang Hospital of Shanghai University of Traditional Chinese Medicine, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, ZhuZhou Central Hospital, First People's Hospital of Chenzhou, People's Hospital of Quzhou, Xuzhou New Health Hospital, Taizhou Enze Medical Center Group, Beijing Chao Yang Hospital, Civil Aviation General Hospital, Xuanwu Hospital, Beijing, Beijing Friendship Hospital, Peking University People's Hospital, Beijing Electric Power Hospital, Renmin Hospital of Wuhan University, Wuhan No.1 Hospital, Jingzhou Central Hospital, The First Affiliated Hospital of Dalian Medical University, Ansteel Group General Hospital, General Hospital of Fuxin Mining Industry Group of Liaoning Health Industry Group, The First Affiliated Hospital of Zhengzhou University, Huaihe Hospital of Henan University, Zhoukou Central Hospital, The First Affiliated Hospital of Henan University of Science and Technology, First Affiliated Hospital of Nanyang Medical College, Jiaozuo Second People's Hospital, Anyang Area Hospital of Puyang City, Shijiazhuang People's Hospital, Cangzhou Central Hospital, The First Hospital of Hebei Medical University, Handan Central Hospital, The People's Hospital of Langfang City, Xingtai Central Hospital, North China University of Science and Technology, The First Affiliated Hospital of Anhui Medical University, the First Hospital of Anhui University of Science and Technology, Chaohu Hospital of Anhui Medical University, Tongling People's Hospital, Huang Shan People's Hospital, Huaibei Miners General Hospital, The Second Affiliated Hospital of Fujian Medical University, Changzhi Medical College, Linfen No.4 People's Hospital, Shanxi Cardiovascular Hospital, Dazhou First People's Hospital, The Affiliated Hospital Of Southwest Medical University, The Third Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Guangdong Pharmaceutical University, Yangchun People's Hospital, Shaoguan People's Hospital, Guilin People's Hospital, The First Affiliated Hospital of Nanchang University, Ji'an Central People's Hospital, Jiangxi Provincial People's Hopital, People's Hospital of Chongqing, Ankang Central Hospital, Xiangyang Central Hospital, Tianjin Third Central Hospital, General Hospital of Ningxia Medical University, The Second Affiliated Hospital of Hainan Medical University, Lanzhou University Second Hospital, Jilin Provincial People's Hospital, Inner Mongolia Autonomous Region People's Hospital, Yan'an Affiliated Hospital of Kunming Medical University, The People's Hospital of Jizhou District, Tianjin, The Southwest Hospital of Army Medical University, The First People's Hospital of Nanning, The People' s Hospital of Jiangmen, The second People's Hospital of Guiyang, The Third People's Hospital of Chengdu, The Tirst People's Hospital of Mianyang, First Affiliated Hospital of Fujian Medical University, The First People's Hospital of Chu Zhou, Xuancheng People's Hospital
Conditions Acute Myocardial Infarction (AMI), Percutaneous Coronary Intervention (PCI)
Enrollment 9,588 participants
Start Date 2025-09-01
Primary Completion 2028-12 (estimated)
Study Completion 2029-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-04